methotrexate + vincristine

Methotrexate + vincristine is a combination chemotherapy regimen consisting of two antineoplastic agents frequently used together in the treatment of various malignancies, including acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma, and advanced breast cancer. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, thereby blocking DNA synthesis and cell replication. Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and arresting cells in metaphase during mitosis. The combination exploits different mechanisms to maximize cytotoxicity against rapidly dividing tumor cells. The sequence of administration can influence efficacy; studies have shown synergistic effects when methotrexate precedes vincristine by 8–24 hours[1][6]. This regimen may be part of multi-agent protocols or used with other drugs depending on the specific cancer type.

Other names

methotrexate and vincristineMTX + VCR